枸地氯雷他定注射液的抗过敏药效研究

发布时间：2018-06-26 13:07

本文选题：枸地氯雷他定注射液 + 血管通透性　；参考：《中国新药杂志》2015年17期

【摘要】：目的:探讨枸地氯雷他定注射液的抗过敏作用。方法:应用组胺致大鼠皮肤血管通透性增加、4-氨基吡啶(4-AP)致小鼠瘙痒和组胺致豚鼠哮喘模型,评价枸地氯雷他定注射液的抗过敏作用。结果:枸地氯雷他定注射液各组能明显抑制皮内注射25或50μg组胺后引起的大鼠皮肤血管通透性增高(P0.01),有效减少了皮肤的蓝染面积。枸地氯雷他定注射液各组对组胺致豚鼠哮喘有明显的拮抗作用,显著延长休克潜伏期(P0.01)。枸地氯雷他定注射液中、高剂量组能显著延长4-AP致小鼠瘙痒的潜伏期及减少瘙痒次数(P0.01)。结论:初步验证了枸地氯雷他定注射液的抗过敏疗效。
[Abstract]:Objective: to study the anti-allergic effect of clodesloratadine injection. Methods: histamine-induced rat skin vascular permeability increased by 4-aminopyridine (4-AP) -induced pruritus and histamine-induced asthma model in guinea pigs, and the antiallergic effect of clodesloratadine injection was evaluated. Results: clodesloratadine injection could significantly inhibit the increase of skin vascular permeability induced by intradermal injection of 25 or 50 渭 g histamine (P0.01) and reduce the area of skin blue staining. The guinea-pig asthma induced by histamine was antagonized by clodesloratadine injection, and the latent period of shock was prolonged (P0.01). In the high dose group, the latencies of pruritus induced by 4-AP were significantly prolonged and the number of itching was decreased (P0.01). Conclusion: the anti-allergic effect of clodesloratadine injection was preliminarily verified.
【作者单位】：中国药科大学药学院;
【分类号】：R965

【参考文献】